VB-111, is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors, that we are initially developing for recurrent glioblastoma. We have obtained Fast Track designation for VB-111 in the United States. We have also received Orphan Drug designation in both the United States and Europe.




VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing. The trial is being conducted in the US, Canada and Israel. Top-line results are expected in 1Q2018.

 For more information please click here.